cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30760799
title: Supplementary Material for: Clinicomics for predicting HER2 expression in metastatic colorectal cancer: a multicenter machine learning analysis on real-world data

description: Background: 
HER2 is expressed in a minority of patients with metastatic colorectal cancer (mCRC), yet it has proven to be a valuable therapeutic target for novel agents such as trastuzumab deruxtecan and tucatinib. Currently, testing is not mandatory in mCRC at baseline and a simple clinical tool to identify patients with a higher likelihood of being HER2-positive would be extremely helpful in guiding test requests and personalized medicine. 
Methods: 
Two machine learning (ML) algorithms were applied to analyze 30 variables available in routine clinical practice (clinicomics) for the prediction of both overall HER2 expression (immunohistochemistry[IHC] score 1 to 3) and HER2 positivity (IHC score 3 or score 2 with ERBB2 gene amplification). Variables identified as relevant in a training cohort were selected to build an easy-to-use predictive model, whose utility was validated in a separate validation cohort. 
Results: 
ML algorithms consistently showed that hemoglobin (Hb) &lt;12 g/dL, carcinoembryonic antigen (CEA) &gt;100 ng/mL, height &gt;160 cm, and the presence of lymph node metastases were significantly associated with HER2 expression in the training cohort (n=293). A model using these four variables had an area under the curve(AUC) of 67%(p = 0.0002). Patients with the presence of all predictive factors had a HER2 expression prevalence of 55%, compared to 15% in patients with none of the predictive factors(p &lt; 0.0001), while HER2 positivity prevalence was 36% vs. 0%, respectively(p &lt; 0.0001). The results were confirmed in the validation cohort(n=96): AUC 68%(p = 0.004); difference in HER2 expression and positivity 58% vs. 12% (p = 0.005) and 47% vs. 0% (p = 0.0002), respectively. 
Conclusions: 
Hb &lt;12 g/dL, CEA &gt;100 ng/mL, height &gt;160 cm, and the presence of lymph node metastases were associated with HER2 expression and positivity. HER2 testing should be considered mandatory when all these factors are present. The mechanisms linking these four factors to HER2 expression require further investigation.
DOI: 10.6084/m9.figshare.30760799.v1
title: Supplementary Material for: Clinicomics for predicting HER2 expression in metastatic colorectal cancer: a multicenter machine learning analysis on real-world data

description: Background: 
HER2 is expressed in a minority of patients with metastatic colorectal cancer (mCRC), yet it has proven to be a valuable therapeutic target for novel agents such as trastuzumab deruxtecan and tucatinib. Currently, testing is not mandatory in mCRC at baseline and a simple clinical tool to identify patients with a higher likelihood of being HER2-positive would be extremely helpful in guiding test requests and personalized medicine. 
Methods: 
Two machine learning (ML) algorithms were applied to analyze 30 variables available in routine clinical practice (clinicomics) for the prediction of both overall HER2 expression (immunohistochemistry[IHC] score 1 to 3) and HER2 positivity (IHC score 3 or score 2 with ERBB2 gene amplification). Variables identified as relevant in a training cohort were selected to build an easy-to-use predictive model, whose utility was validated in a separate validation cohort. 
Results: 
ML algorithms consistently showed that hemoglobin (Hb) &lt;12 g/dL, carcinoembryonic antigen (CEA) &gt;100 ng/mL, height &gt;160 cm, and the presence of lymph node metastases were significantly associated with HER2 expression in the training cohort (n=293). A model using these four variables had an area under the curve(AUC) of 67%(p = 0.0002). Patients with the presence of all predictive factors had a HER2 expression prevalence of 55%, compared to 15% in patients with none of the predictive factors(p &lt; 0.0001), while HER2 positivity prevalence was 36% vs. 0%, respectively(p &lt; 0.0001). The results were confirmed in the validation cohort(n=96): AUC 68%(p = 0.004); difference in HER2 expression and positivity 58% vs. 12% (p = 0.005) and 47% vs. 0% (p = 0.0002), respectively. 
Conclusions: 
Hb &lt;12 g/dL, CEA &gt;100 ng/mL, height &gt;160 cm, and the presence of lymph node metastases were associated with HER2 expression and positivity. HER2 testing should be considered mandatory when all these factors are present. The mechanisms linking these four factors to HER2 expression require further investigation.
DOI: 10.6084/m9.figshare.30760802
title: Supplementary Material for: INTRAUTERINE TREATMENT IN TWO FETUSES AFFECTED BY CYSTIC FIBROSIS.TO WHOM AND SINCE WHEN?REPORT OF CASES.

description: Introduction: Cystic fibrosis (CF) is an autosomal recessive disease asociated to low survival disease into adulthood. The appearance of the cystic fibrosis transmembrane conductance regulator (CFTR) therapy has revolutionized the management and the prognosis of this patients with an improvement in the pancreatic and lung function with a much better quality of life. More women with CF are considering being mothers. Other clinical scenario is the prenatal diagnosis of fetus with CF. Three cases reports have been published suggesting that CFTR therapy during pregnancy in fetuses affected by CF might prevent prenatal meconium ileous (MI), which are the one who have a higher risk of gastrointestinal morbidity and long-term complications. 

Case presentation: We present two cases reports in which the diagnosis of CF occurred during intrauterine life and treatment with CFTR therapy was administered to healthy pregnant women in order to reduce the risk MI in their fetuses. In both cases the diagnosis suspicion was by ultrasound findings with a genetic confirmed diagnosis by amniocentesis. In the first case, the mother received the CTFR therapy during five weeks and MI was not developed by the newborn. In the second one, the mother received the treatment only for a week and MI could not be avoided. 

Conclusion: This clinical situation has special ethical considerations, since a drug is being administered through compassionate use to a women who does not need it. The fundamental reason is the lack of authorization for the use of these drugs in newborns but in adults. We hope that these two clinical cases, together with those already published, will increase the knowledge and experience of using this drug in this context helping with the management of pregnant women with fetuses affected by CF in order to reduce associated complications.
DOI: 10.6084/m9.figshare.30760802.v1
title: Supplementary Material for: INTRAUTERINE TREATMENT IN TWO FETUSES AFFECTED BY CYSTIC FIBROSIS.TO WHOM AND SINCE WHEN?REPORT OF CASES.

description: Introduction: Cystic fibrosis (CF) is an autosomal recessive disease asociated to low survival disease into adulthood. The appearance of the cystic fibrosis transmembrane conductance regulator (CFTR) therapy has revolutionized the management and the prognosis of this patients with an improvement in the pancreatic and lung function with a much better quality of life. More women with CF are considering being mothers. Other clinical scenario is the prenatal diagnosis of fetus with CF. Three cases reports have been published suggesting that CFTR therapy during pregnancy in fetuses affected by CF might prevent prenatal meconium ileous (MI), which are the one who have a higher risk of gastrointestinal morbidity and long-term complications. 

Case presentation: We present two cases reports in which the diagnosis of CF occurred during intrauterine life and treatment with CFTR therapy was administered to healthy pregnant women in order to reduce the risk MI in their fetuses. In both cases the diagnosis suspicion was by ultrasound findings with a genetic confirmed diagnosis by amniocentesis. In the first case, the mother received the CTFR therapy during five weeks and MI was not developed by the newborn. In the second one, the mother received the treatment only for a week and MI could not be avoided. 

Conclusion: This clinical situation has special ethical considerations, since a drug is being administered through compassionate use to a women who does not need it. The fundamental reason is the lack of authorization for the use of these drugs in newborns but in adults. We hope that these two clinical cases, together with those already published, will increase the knowledge and experience of using this drug in this context helping with the management of pregnant women with fetuses affected by CF in order to reduce associated complications.
DOI: 10.6084/m9.figshare.30760805
title: Supplementary Material for: Safe Administration of Fruquintinib in a Hemodialysis Patient with Metastatic Colorectal Cancer: A Case Report

description: **Background:** 
Fruquintinib is a selective vascular endothelial growth factor receptor (VEGFR) inhibitor approved for metastatic colorectal cancer (mCRC) that is refractory to standard therapies. While its efficacy and safety have been demonstrated in phase III trials, data on its use in patients undergoing hemodialysis for end-stage renal disease (ESRD) are lacking. We report the first known case of fruquintinib administration in a patient undergoing maintenance hemodialysis.

**Case Presentation:** 
A 66-year-old woman with mCRC and ESRD undergoing thrice-weekly hemodialysis received multiple lines of chemotherapy, including FOLFOX, FOLFIRI, and regorafenib. Owing to progressive disease and limited treatment options, fruquintinib was initiated after informed consent was obtained. The starting dose was 3 mg/day, with escalation to 4 mg, and subsequently to 5 mg in later cycles. The drug was administered daily regardless of the dialysis schedule. Adverse events, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, included Grade 1 fatigue and diarrhea and Grade 3 anemia requiring transfusion, which was attributed to underlying renal anemia rather than fruquintinib. Clinically significant hypertension, electrolyte disturbances, or other toxicities were not observed. Despite acceptable tolerability, computed tomography (CT) after three cycles indicated disease progression.

**Conclusion:** 
This case suggests that fruquintinib may be administered safely to selected patients with mCRC on maintenance hemodialysis. Further data are needed to establish dosing strategies and monitor potential toxicities in this population.
DOI: 10.6084/m9.figshare.30760805.v1
title: Supplementary Material for: Safe Administration of Fruquintinib in a Hemodialysis Patient with Metastatic Colorectal Cancer: A Case Report

description: **Background:** 
Fruquintinib is a selective vascular endothelial growth factor receptor (VEGFR) inhibitor approved for metastatic colorectal cancer (mCRC) that is refractory to standard therapies. While its efficacy and safety have been demonstrated in phase III trials, data on its use in patients undergoing hemodialysis for end-stage renal disease (ESRD) are lacking. We report the first known case of fruquintinib administration in a patient undergoing maintenance hemodialysis.

**Case Presentation:** 
A 66-year-old woman with mCRC and ESRD undergoing thrice-weekly hemodialysis received multiple lines of chemotherapy, including FOLFOX, FOLFIRI, and regorafenib. Owing to progressive disease and limited treatment options, fruquintinib was initiated after informed consent was obtained. The starting dose was 3 mg/day, with escalation to 4 mg, and subsequently to 5 mg in later cycles. The drug was administered daily regardless of the dialysis schedule. Adverse events, graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, included Grade 1 fatigue and diarrhea and Grade 3 anemia requiring transfusion, which was attributed to underlying renal anemia rather than fruquintinib. Clinically significant hypertension, electrolyte disturbances, or other toxicities were not observed. Despite acceptable tolerability, computed tomography (CT) after three cycles indicated disease progression.

**Conclusion:** 
This case suggests that fruquintinib may be administered safely to selected patients with mCRC on maintenance hemodialysis. Further data are needed to establish dosing strategies and monitor potential toxicities in this population.
DOI: 10.6084/m9.figshare.30760808
title: Supplementary Material for: Prevalence and factors associated with sarcopenia in community-dwelling older adults: a systematic review and meta-analysis

description: Background: Sarcopenia is a growing concern as a geriatric syndrome associated with various adverse health outcomes. Determining its prevalence and identifying risk factors are essential for effective prevention.
Objective: This systematic review and meta-analysis aimed to estimate the prevalence of sarcopenia and identify the factors associated with sarcopenia in community-dwelling older adults.
Methods: Guided by the PICo framework, we systematically searched six databases for relevant literature. Two reviewers independently assessed the quality of included studies. We performed a meta-analysis to estimate the prevalence of sarcopenia in overall older adults and subgroups. For risk factor analysis, pooled odds ratios (ORs) with 95% CIs were calculated, employing either random or fixed-effects models as appropriate.
Results: A total of 52 eligible studies involving 70,202 older adults were included, among whom 7,488 were male and 9,054 were female. 40 studies were analyzed for both prevalence and related factors, while the remaining 12 were used for prevalence estimation only. The pooled analysis revealed a wide variation in the prevalence of sarcopenia among community-dwelling older adults, ranging from 5.2% to 50.0%, with an overall estimated prevalence of 18.8% (95% CI: 15.6%-22.4%) and substantial heterogeneity (I²=99.3%). Subgroup analyses showed that the highest rates were identified in studies using the EWGSOP 2018 definition (25.8%), Europe populations (23.4%), and using the anthropometric equations for muscle mass measurement (23.1%). Moreover, the factors significantly associated with sarcopenia in community-dwelling older adults were older age (OR = 3.3, 95% CI: 2.8–3.8), BMI (OR = 0.7, 95% CI: 0.6–0.9), malnutrition (OR = 3.4, 95% CI: 2.2–5.1), low physical activity (OR = 2.3, 95% CI: 1.8–2.8), current smoking (OR = 1.7, 95% CI: 1.3–2.2), and comorbidities such as osteoporosis (OR = 1.8, 95% CI: 1.3–2.4), osteoarthritis (OR = 1.4, 95% CI: 1.3–1.6), depression (OR = 3.0, 95% CI: 1.9–4.7), diabetes (OR = 2.8, 95% CI: 1.4–5.4), and cognitive impairment (OR = 2.5, 95% CI: 1.9–3.2).
Conclusion: Our findings demonstrate a high prevalence of sarcopenia among community-dwelling older adults, with estimates significantly influenced by geographic region, diagnostic criteria and muscle mass measurement methods. The findings highlight heterogeneity due to non-standardized diagnostic methods and identify key risk factors including advanced age, low BMI, malnutrition, low physical activity, and comorbidities such as osteoporosis. These results underscore the need for unified diagnostic standards and early community-based interventions targeting modifiable risks.
DOI: 10.6084/m9.figshare.30760808.v1
title: Supplementary Material for: Prevalence and factors associated with sarcopenia in community-dwelling older adults: a systematic review and meta-analysis

description: Background: Sarcopenia is a growing concern as a geriatric syndrome associated with various adverse health outcomes. Determining its prevalence and identifying risk factors are essential for effective prevention.
Objective: This systematic review and meta-analysis aimed to estimate the prevalence of sarcopenia and identify the factors associated with sarcopenia in community-dwelling older adults.
Methods: Guided by the PICo framework, we systematically searched six databases for relevant literature. Two reviewers independently assessed the quality of included studies. We performed a meta-analysis to estimate the prevalence of sarcopenia in overall older adults and subgroups. For risk factor analysis, pooled odds ratios (ORs) with 95% CIs were calculated, employing either random or fixed-effects models as appropriate.
Results: A total of 52 eligible studies involving 70,202 older adults were included, among whom 7,488 were male and 9,054 were female. 40 studies were analyzed for both prevalence and related factors, while the remaining 12 were used for prevalence estimation only. The pooled analysis revealed a wide variation in the prevalence of sarcopenia among community-dwelling older adults, ranging from 5.2% to 50.0%, with an overall estimated prevalence of 18.8% (95% CI: 15.6%-22.4%) and substantial heterogeneity (I²=99.3%). Subgroup analyses showed that the highest rates were identified in studies using the EWGSOP 2018 definition (25.8%), Europe populations (23.4%), and using the anthropometric equations for muscle mass measurement (23.1%). Moreover, the factors significantly associated with sarcopenia in community-dwelling older adults were older age (OR = 3.3, 95% CI: 2.8–3.8), BMI (OR = 0.7, 95% CI: 0.6–0.9), malnutrition (OR = 3.4, 95% CI: 2.2–5.1), low physical activity (OR = 2.3, 95% CI: 1.8–2.8), current smoking (OR = 1.7, 95% CI: 1.3–2.2), and comorbidities such as osteoporosis (OR = 1.8, 95% CI: 1.3–2.4), osteoarthritis (OR = 1.4, 95% CI: 1.3–1.6), depression (OR = 3.0, 95% CI: 1.9–4.7), diabetes (OR = 2.8, 95% CI: 1.4–5.4), and cognitive impairment (OR = 2.5, 95% CI: 1.9–3.2).
Conclusion: Our findings demonstrate a high prevalence of sarcopenia among community-dwelling older adults, with estimates significantly influenced by geographic region, diagnostic criteria and muscle mass measurement methods. The findings highlight heterogeneity due to non-standardized diagnostic methods and identify key risk factors including advanced age, low BMI, malnutrition, low physical activity, and comorbidities such as osteoporosis. These results underscore the need for unified diagnostic standards and early community-based interventions targeting modifiable risks.
DOI: 10.6084/m9.figshare.30760811
title: Supplementary Material for: Life-threatening Upper Gastrointestinal Bleeding Following Percutaneous Endoscopic Gastrostomy Tube Removal Under Traction: A Case Report

description: Introduction: Percutaneous endoscopic gastrostomy (PEG) tubes are commonly used to facilitate long-term enteral nutrition. Selected PEG tubes may be appropriately removed without endoscopic guidance via gentle traction, which is seldom associated with major bleeding sequelae. Rare reports of major upper gastrointestinal (GI) hemorrhage following PEG tube removal have been managed using Foley catheter balloon tamponade or endoscopic over-the-scope clipping. Prompt reinsertion of a PEG tube may also be considered. Case presentation: We present the case of a multi-morbid 73-year-old female who experienced life-threatening hemodynamically unstable upper GI bleeding following traction PEG tube removal which proved refractory to standard endoscopic measures of adrenaline injection and hemostatic clipping, as well as rotational thromboelastometry-guided correction of consumptive coagulopathy. There was no suitable target for angioembolization. Ultimately, in the context of continued hemodynamically unstable GI bleeding, definitive surgical hemostasis – a mode of intervention not frequently reported for bleeding of this nature – was achieved during emergency laparotomy via complete excision of the PEG tract and wedge excision of the involved stomach wall. Conclusion: Life-threatening hemodynamically unstable GI bleeding rarely complicates traction PEG tube removal. In elderly patients with multiple co-morbidities, PEG tract bleeding refractory to standard endotherapy and not targetable by angioembolization can be safely and effectively managed with timely surgical intervention.
DOI: 10.6084/m9.figshare.30760811.v1
title: Supplementary Material for: Life-threatening Upper Gastrointestinal Bleeding Following Percutaneous Endoscopic Gastrostomy Tube Removal Under Traction: A Case Report

description: Introduction: Percutaneous endoscopic gastrostomy (PEG) tubes are commonly used to facilitate long-term enteral nutrition. Selected PEG tubes may be appropriately removed without endoscopic guidance via gentle traction, which is seldom associated with major bleeding sequelae. Rare reports of major upper gastrointestinal (GI) hemorrhage following PEG tube removal have been managed using Foley catheter balloon tamponade or endoscopic over-the-scope clipping. Prompt reinsertion of a PEG tube may also be considered. Case presentation: We present the case of a multi-morbid 73-year-old female who experienced life-threatening hemodynamically unstable upper GI bleeding following traction PEG tube removal which proved refractory to standard endoscopic measures of adrenaline injection and hemostatic clipping, as well as rotational thromboelastometry-guided correction of consumptive coagulopathy. There was no suitable target for angioembolization. Ultimately, in the context of continued hemodynamically unstable GI bleeding, definitive surgical hemostasis – a mode of intervention not frequently reported for bleeding of this nature – was achieved during emergency laparotomy via complete excision of the PEG tract and wedge excision of the involved stomach wall. Conclusion: Life-threatening hemodynamically unstable GI bleeding rarely complicates traction PEG tube removal. In elderly patients with multiple co-morbidities, PEG tract bleeding refractory to standard endotherapy and not targetable by angioembolization can be safely and effectively managed with timely surgical intervention.
DOI: 10.15468/dl.nb3srf
title: Occurrence Download

description: A dataset containing 11 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "Country is United States of America",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Epimedium grandiflorum"
 ]
}

 The dataset includes 11 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0021712-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.njhjtz
title: Occurrence Download

description: A dataset containing 359 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((120.1561111173514 22.98658098064403,120.18868669700637 22.98658098064403,120.18868669700637 23.019156560299006,120.1561111173514 23.019156560299006,120.1561111173514 22.98658098064403))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Platalea minor",
 "Year 2005-2025"
 ]
}

 The dataset includes 359 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0021711-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.zyz9t9
title: Occurrence Download

description: A dataset containing 11 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "Country is United States of America",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Epimedium grandiflorum"
 ]
}

 The dataset includes 11 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0021713-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.71947/arim.jpmxp1225tu5016-1
title: 積層配線_Au250_Ni200_Cr100_cleaning_liftoff_
DOI: 10.71947/arim.jpmxp1225tu5016-2
title: 積層配線_Au500_Ni200_Cr10_cleaning_liftoff_
DOI: 10.71947/arim.jpmxp1225tu5016-3
title: 積層配線_Au500_Ni100_Cr100_cleaning_liftoff_